German Multicenter Trial for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.
Lymphoma, Lymphoblastic
DRUG: Dexamethasone/Prednisolone|DRUG: Cyclophosphamide|DRUG: Vincristine|DRUG: Daunorubicin|DRUG: Asparaginase|DRUG: G-CSF|DRUG: Mercaptopurine|DRUG: Cytarabine|DRUG: Methotrexate|DRUG: VP16|DRUG: Vindesine|DRUG: Adriamycin|DRUG: Thioguanine|DRUG: HDARAC|PROCEDURE: CNS irradiation|PROCEDURE: Mediastinal irradiation|DRUG: Cladribine
remission rate, remission duration, disease free survival, overall survival
time and dose compliance, toxicity according to World Health Organization (WHO)
This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma (T-LBL) according to a protocol for acute lymphoblastic leukemia. Patients receive one year of intensive cyclical chemotherapy with additional prophylaxis for central nervous system (CNS) relapse by intrathecal therapy and cranial irradiation and mediastinal irradiation after induction chemotherapy.